t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.


    Susanne Knigge (CEO)

    Susanne Knigge is CEO of t2cure since January 2010. She previously served in this role during the start up phase of the company from 2005 to 2008. She continued as a legal consultant. Ms. Knigge has 20 years of experience in the biotechnology and pharma industry. She was active in several company launches and served as a member of the board. Ms. Knigge graduated from Heidelberg University law school and is registered as a lawyer in Hamburg since 1991.